Changes in the Properties of the Thyrotropin Receptor Antibody in Patients with Graves` Disease after Radioiodine Treatment

Bo Youn Cho; Young Kee Shong; June-Key Chung; Myung Chul Lee; Hong Kyu Lee; Chang-Soon Koh; Hun Ki Min

doi:10.3904/kjim.1990.5.1.51

Korean J Intern Med > Volume 5(1); 1990 > Article

Cho, Shong, Chung, Lee, Lee, Koh, and Min: Changes in the Properties of the Thyrotropin Receptor Antibody in Patients with Graves’ Disease after Radioiodine Treatment

Original Article

The Korean Journal of Internal Medicine 1990;5(1):51-57.

DOI: https://doi.org/10.3904/kjim.1990.5.1.51

Changes in the Properties of the Thyrotropin Receptor Antibody in Patients with Graves’ Disease after Radioiodine Treatment

Bo Youn Cho, M.D., Young Kee Shong, M.D.^*, June-Key Chung, M.D., Myung Chul Lee, M.D., Hong Kyu Lee, M.D., Chang-Soon Koh, M.D., Hun Ki Min, M.D.

Department of Internal Medicine, Seoul National University, College of Medicine, Seoul, Korea

Address reprint requests: Bo Youn Cho, M.D., Department of Internal Medicine, Seoul National University Hospital, 28 Yongon-dong, Chongno-gu, Seoul, 110-744, Korea

Supported by:

This study was supported in part by a Clinical Research Grant (1989) from Seoul National University Hospital.

Current address:

^*Present address: Department of Internal Medicine, Asan Medical Center, Seoul, Korea

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

We investigated the effect of a single dose of ¹³¹I upon thyrotropin receptor antibodies (TRAb) in 21 patients with Graves’ disease. The thyrotropin receptor antibodies were assessed by parallel measurements of thyrotropin binding inhibitor immunoglobulin (TBII), thyroid stimulating antibody (TSAb) and thyroid stimulation blocking antibody (TSBAb) in serum by radoreceptor assay, stimulation of adenlate cyclase and inhibition of TSH-stimulated adenylate cyclase activation in FRTL-5 cells, respectively. Prior to radioiodine treatment, TBII was detected in all 21 patients and TSAb in 19 patients. After radioiodine treatment, TBII activities did not change during the 12-months observation period, but in eight patients TSAb activities gradually decreased and were undetectable at the end of the 12-month observation period. Persistence of TSAb was not associated with the clinical outcome. Eight patients developed hypothyroidism within one year after radioiodine treatment. Three of the hypothyroid patients developed TSBAb, and the appearance of TSBAb coincided with the development of hypothyroidism. These results suggest that TSBAb might develop after radioiodine treatment in a minority of patients with Graves’ disease and that the appearance of TSBAb, in addition to radiation-induced thyroid destruction, might be involved in the development of hypothyroidism following radioiodine treatment.

Keywords: Graves’ disease; Radioiodine; Thyrotropin receptor antibody; Hypothyroidism

INTRODUCTION

It is widely accepted that antibodies against the TSH receptor may play an important role in the cause of hyperthyroidism in Graves’ disease¹⁾. The activity of these antibodies can be estimated by direct biological activity, termed thyroid stimulating antibody (TSAb), or by their ability to inhibit the binding of radiolabeled thyrotropin to thyroid membranes, termed thyrotropin binding inhibitor immunoglobulins (TBII). It has recently been reported that immunoglobulins in primary nongoitrous myxedema not only inhibit the binding of TSH to its receptor, but also inhibit TSH-stimulated adenylate cyclase activation in cultured thyroid cells^2,3), and these thyroid stimulation blocking antibodies (TSBAb) may play a role in the development of hypothyroidism and thyroid atrophy in primary nongoitrous myxedema⁴⁾.

After radioiodine treatment for Graves’ hyperthyroidism, a transient increase, followed by a decline in TSH receptor antibodies (TRAb), has been well-documented^5–9). Recently, it has been reported that TSBAb develop in patients with Graves’ disease during antithyroid drug treatment¹⁰⁾ or after radioiodine treatment^11,12). However, it is still uncertain whether changes in the properties of TRAb after radioiodine treatment, especially development of TSBAb, could alter the clinical outcome of Graves’ disease.

In the present study, we simultaneously meausred TBII, TSAb and TSBAb activities sequentially after a single dose of ¹³¹I and compared their activities with the functional status of the thyroid in patients with Graves’ disease.

MATERIALS AND METHODS

1. Patients

Twenty-one patients (10 male, 11 female), ranging in age from 15 to 72 years (mean age: 42 years), were studied. The diagnosis of Graves’ hyperthyroidism was based on clinical findings, elevated serum T4 level, decreased serum TSH level and increased thyroidal ¹³¹I uptake. No patients had been previously treated with ¹³¹I. Six of the patients received ¹³¹I as the first-line therapy, and the remainder were treated with antithyroid drugs for 12–70 months before ¹³¹I treatment.

Thyroid weight was estimated by palpation and scintiscan, and 100–150 uCi of ¹³¹I per gram of thyroid tissue was administered (4–15 mCi, mean±SD: 9.1±2.1 mCi). All patients were treated with methimazole for one or two months after the ¹³¹I administration, and if a relapse occurred, antithyroid medications were given until the completion of the study. After radioiodine treatment, blood samples were taken at three-month intervals up to 12 months. The IgG fraction was isolated from the serum samples by means of affinity chromatography on columns of protein A-Sepharose CL-4B (Pharmacia, Uppsala, Sweden). Thyroid function tests were done with commercially available RIA kits.

2. Assay for TBII

TBII was measured as previously described¹³⁾ using a commercial radioreceptor assay kit (R.S.R. Ltd., Cardiff, Wales, UK). TBII activity was expressed as the percent inhibition of ¹²⁵I-bTSH binding to the TSH receptor. A TBII value exceeding 20% was considered abnormal or positive.

3. Assay for TSAb and TSBAb

FRTL-5 cells, kindly supplied by Dr. L.D. Kohn (NIH, Bethesda, MD., USA), were maintained as previously described¹⁴⁾ and also maintained for seven days in a medium without TSH before the assay. The medium was changed with 300 ul of test IgG (10 g/l). IgGs were dissolved in Hank’s balanced salt solution (HBSS) without NaCl containing 0.5 mmol/l IBMX, 20 mmol/l HEPES, and 1.0% BSA, pH 7.4. After 2 h incubation at 37°C, cAMP released into the medium was measured by RIA (Immunonuclear, Stillwater, Minn., USA). The assay system was sensitive to 5 mU/l bTSH with a response of 1.71±0.07 times the basal cAMP level. All samples were run in triplicate. The intrassay variance was 8.2–12.1%, and the interassay variance was 17.1–30.5%. TSAb activity was expressed as a % increase in cAMP production by test IgG in comparison with normal IgG. TSAb was defined as positive when the value was greater than 2 SD above the mean value produced by the IgG fraction from 24 normal subjects (>170%).

For the assay of TSBAb, test IgG was incubated with or without 0.1 U/l bTSH. Other procedures were the same as in the TSAb assay. TSBAb activity was expressed as a % inhibition of the TSH-stimulated cAMP increase and was calculated as follows: TSBAb (%) = 100 × [1 − (cAMP under 0.1 U/l bTSH with test IgG-cAMP under normal IgG)/(cAMP under 0.1 U/l bTSH with normal IgG-cAMP under normal IgG)]. TSBAb was defined as positive when the value was greater than 2 SD above the mean value produced by the IgG fractions from 24 normal subjects (>37%).

4. Statistical Analysis

Statistical analysis was done with a Fisher’s exact test and Wilcoxon rank sum test. Statistical significance was defined as having a P-value below 0.05.

RESULTS

Before radioiodine treatment, TBII was detected in all 21 patients, and TSAb was detected in 19 out of 21. The individual changes of TBII and TSAb activities after radioiodine treatment were variable. TBII activities increased in six patients, decreased in six and remained unchanged in nine; TSAb activities increased in four, decreased in 11 and did not change in four patients during the 12-month observation period (Table 1, Fig. 1). The changes of TBII and TSAb activities were not associated with pretreatment with antithyroid drugs (Table 1). At 12 months after radioiodine treatment, TBII was still present in all of the patients, but TSAb activity was not detected in eight patients, including the two in whom TSAb was undetectable before radioiodine treatment (Table 1). Between the patients whose TSAb activities persisted and those whose TSAb activities disappeared, there were no differences in age, sex, dose of ¹³¹I, duration of antithyroid drug treatment and titers of antimicrosomal and/or antithyroglobulin antibody. But TSAb activity before radioiodine treatment was significaltly higher in patients whose TSAb continued to persist than in those whose TSAb disappeared (Table 2).

Twelve months after radioiodine treatment, eight patients had become hypothyroid, 10 were in remission and three had relapsed. The patients’ outcomes were not associated with TSAb activites at three and/or 12 months after radioiodine treatment. Pretreatment with antithyroid drugs did not affect the clinical outcome. Four out of eight patients who became hypothyroid were negative of TSAb activities. Of them, three patients had developed TSBAb during the observation peroid. All these patients became hypothyroid three to six months after radioiodine treatment, requiring thyroxine replacement (Table 3). Their TBII activities were potent before radioiodine administration and did not change after radioiodine treatment. But TSAb activities decreased gradually and disappeared within six months after radioiodine treatment, followed by a sudden appearance of TSBAb, coinciding with the development of hypothyroidism (Fig. 2). TSBAb activities were not found in any of the patients before radioiodine treatment.

DISCUSSION

In this study, we found that in contrast to previous reports^8,9) TBII persisted for 12 months after radioiodine treatment in all patients. This discrepancy may be due to the differences in the patients selected and the short observation period. Most of the patients in this study were resistant to the long-term antithyroid drug treatment and had high TBII activities before radioiodine treatment. Moreover, TBII activities did not change or decrease at three months after radioiodine treatment in 15 out of 21 patients. In this study, all the patients were treated with antithyroid drugs for two or more months after radioiodine treatment. Their use after radioiodine treatment may have prevented a transient increase in TRAb activities. Changes of TSAb activities after radioiodine treatment varied. TSAb activities did not change for 12 months in 13 out of 21 patients. However, in six patients TSAb activities decreased gradually and then disappeared, while TBII persisted in high titers. This dissociation between TSAb and TBII activities suggests the development of different types of antibodies against the TSH receptor.

An interesting finding in this study is the development of TSBAb after radioiodine treatment in three out of 21 patients with Graves’ disease. All of them had both TBII and TSAb activities before radioiodine treatment. After radioiodine treatment, TSAb activities disappeared within six months and were followed by a sudden appearance of TSBAb activities. IgGs from these three patients inhibited not only the binding of TSH to its receptor but also a TSH-stimulated cAMP increase in FRTL-5 cells. Moreover, all of them developed hypothyroidism in accordance with the appearance of TSBAb. It is well-known that radioiodine therapy induces cell damage of the thyroid gland and results in hypothyroidism, but the present findings suggest that the appearance of TSBAb is in some cases related to the development of hypothyroidism.

The mechanism of changes in the properties of TRAb after radioiodine therapy in Graves’ disease is still unknown. Since we had used antithyroid drugs for several months before radioiodine treatment, the potential effects of antithyroid drugs on the properties of TRAb and their activities should be considered. However, we could not find any correlation between the pretreatment with antithyroid drugs and the clinical outcome after radioiodine treatment. It may be speculated that radioiodine not only causes a release of large amounts of antigens but also alters immune homeostasis in the thyroid gland, resulting in changes in the properties of TRAb. Although the incidence of the development of TSAb after radioiodine therapy is not frequent, out findings suggest that thyroid function after radioiodine treatment in Graves’ disease may be affected by changes in the properties of TRAb. Moreover, Furmaniak et al.¹⁵⁾ recently described an interesting patient with Graves’ disease who developed TSBAb and hypothyroidism after radioiodine treatment, and TSBAb disappeared spontaneously with a reappearance of TSAb and hyperthyroidism. The clinical status of Graves’ disease might therefore be a result of the balance between the activities of stimulating and blocking types of TRAb¹⁶⁾. Measuring several different actions of these TRAb might thus be of value in predicting the development of hypothyroidism in patients following radioiodine treatment.

Fig. 1.

TBII (a) and TSAB (b) activities before and 12 months after radioiodine treatment in 21 patients with Gaves’ disease. The shaded area represents the normal range.

Fig. 2.

Sequential changes in TBII, TSAb and TSBAb activities of three patients who developed TSBAb after radioiodine therapy. Closed circle: TSBAb, open circle: TSAb, closed rectangle: TBII. Closed arrows indicate the time when the patients became hypothyroid. The shaded area represents the normal range.

Table 1.

Changes of TBII and TSAb Activities After Radioiodine Treatment in 21 Patients with Graves’ Disease

Patient Number	¹³¹I (mCi)	TBII (%)					TSAb (%)					Clinical Outcome (months)
		Time after Radioiodine Treatment (months)
		0	3	6	9	12	0	3	6	9	12
Pretreatment with antithyroid drugs
1	8	90.8	76.0	64.0	66.1	69.0	258	168	178	245	301	Hypothyroid (9)
2	6	50.9	63.4	62.5	61.9	51.9	494	2143	1340	993	630	Euthyroid
3	4	85.2	89.2	62.1	63.5	31.9	403	217	356	326	218	Euthyroid
4	7	28.1	90.3	78.1	70.0	62.1	222	425	401	365	359	Euthyroid
5	10	82.9	72.0	67.3	81.9	90.0	385	365	365	1753	2469	Relapse (6)
6	12	77.8	78.2	89.8	89.4	80.3	548	484	499	375	593	Relapse (12)
7	8	38.8	72.5	69.4	78.8	78.0	2667	2104	2449	2716	2700	Euthyroid
8	8	39.6	68.4	78.4	80.0	78.1	180	753	330	340	345	Hypothyroid (9)
9	10	81.4	91.2	95.8	86.0	84.0	800	519	473	276	285	Hypothyroid (6)
10	8	55.2	89.8	82.4	68.8	66.2	108	191	968	247	104	Relapse (6)
11	10	33.4	29.1	28.2	26.5	26.0	79	79	83	105	109	Euthyroid
12^*	15	99.8	91.0	78.9	80.5	76.0	394	321	84	109	133	Hypothyroid (3)
13	10	87.4	55.1	12.2	37.9	32.0	454	404	104	84	104	Hypothyroid (9)
14^*	8	79.8	80.9	85.3	80.4	55.7	316	237	168	109	100	Hypothyroid (6)
15	10	75.6	76.1	56.1	37.0	30.3	4914	4490	3134	2245	545	Euthyroid
No pretreatment with antithyroid drugs
16	12	55.2	34.4	26.2	30.5	35.5	5918	326	257	210	257	Euthyroid
17	10	75.0	57.9	41.9	46.3	46.2	7347	6122	5714	380	347	Euthyroid
18	8	27.2	20.9	28.6	23.2	25.1	180	85	83	99	85	Euthyroid
19	10	87.6	82.6	82.5	82.5	82.0	2321	2874	3753	3805	3745	Hypothyroid (6)
20^*	10	90.0	80.5	71.3	80.7	85.2	273	108	99	100	105	Hypothyroid (6)
21	8	71.3	59.7	51.3	69.4	68.6	223	163	104	83	101	Euthyroid

^* Cases who developed TSAb after radioiodine treatment

Table 2.

Initial Clinical and Laboratory Data (mean ± SD) in TSAb Non–disappearing and TSAb Disappearing Groups

	TSAb
	Non-disappearing	Disappearing
Age	44.2±13.3	40.4±16.7	NC
Sex (M:F)	6 : 7	4 : 4	NC
Goiter (g)	63.1±24.3	61.3±21.0	NC
Dose of I (mCi)	8.9±2.3	9.6±2.4	NC
Duration of ATD
Treatment (months)	17.1±14.8	29.0±28.2	NC
AMA^*	4.0±1.6	3.5±1.8	NC
TBII (%)	66.8±21.4	68.1±26.9	NC
TSAb (%)	2035±118^**	254±6^**	p<0.01

NC: not significant, ATD: antithyroid drugs, AMA : antimicrosomal antibody,

^*: Measured by tanned red cell hemagglutination technique using commercial kits (Fujirebio Co., Tokyo, Japan). Values are reciprocals of logarithmic titers.

^**: Meant±SEM

Table 3.

Serial Changes of Thyroid Function and TSH Receptor Antibodies Activities in Three Patients who Developed Hypothyroidism and Thyroid Stimulation Blocking Antibody After Radioiodine Treatment

Patient Number	Time^* (month)	T3 (ng/dl)	T4 (ug/dl)	TSH (uU/ml)	TBII (%)	TSAb (%)	TSBAb (%)	Treatment
12	0	250	14.6	< 0.05	99.8	394	32	¹³¹I 15mCi
	3	67	2.0	41.0	91.0	321	34
	6	86	3.6	120.0	78.9	84	96	T4 150 ug/d
	9	176	10.2	1.7	80.5	109	98	"
	12	158	11.8	1.2	76.0	133	97	"

14	0	315	15.5	< 0.05	79.8	316	33	¹³¹I 8 mCi
	3	102	5.9	14.6	80.9	237	37
	6	92	4.5	105.0	85.3	168	83	T4 100 ug/d
	9	141	10.7	9.1	80.4	109	97	T4 150 ug/d
	12	169	12.5	0.8	85.7	100	98	"

20	0	270	13.0	< 0.05	90.0	273	25	¹³¹I 10 mCi
	3	124	6.2	14.0	80.5	108	96
	6	39	2.1	180.0	71.3	99	95	T4 150 ug/d
	9	166	10.8	1.2	80.7	100	97	"
	12	172	12.0	0.8	85.2	105	96	"

^*: Time after radioiodine treatment

Normal values: T3 85–200 ng/dl; T4 6.7–13.2 ug/dl; TSH 0.4–4.2 uU/ml; TBII −10.0–15%; TSAb < 170%; TSBAb < 37%

REFERENCES

1. Rees Smith B, McLachlan SM, Furmaniak J. Autoantibodies to the thyrotropin receptor. Endocr Rev 9:106. 1988.

2. Endo K, Kasagi K, Konishi J, Ikekubo K, Okuno T, Takeda Y, Mori T, Torizuka K. Detection and properties of TSH-binding inhibitor immunoglobulins in patients with Graves’ disease and Hashimoto’s thyriditis. J Clin Endocrinol Metabol 46:734. 1978.

3. Konishi J, Iida Y, Endo K, Misaki T, Nohara Y, Matsuura N, Mori T, Torizuka K. Inhibition of thyrotropin-induced adenosine 3′,5′-monophosphate increase by immunoglobulins from patients with primary nongoitrous myxedema. J Clin Endocrinol Metabol 57:544. 1983.

4. Cho BY, Shong YK, Lee HK, Koh C-S, Min HK. Inhibition of thyrotropin-stimulated adenylate cyclase activation and growth of rat thyroid cell, FRTL-5, by immunoglobulin G from patients with primary myxedema: comparison with activities of thyrotropin binding inhibitor immunoglobulins. Acta Endocrinol 120:99. 1989.

5. McGregor AM, Petersen MM, Capiferri R, Evered DC, Rees Smith B, Hall R. Effects of radioiodine on thyrotropin binding inhibiting immunoglobulins in Graves’ disease. Clin Endocrinol 11:437. 1979.

6. Teng CS, Yeung RTT, Khoo RKK, Alagaratnam TT. A prospective study of the changes in thyrotropin binding inhibitory immunolobulins in Graves’ disease treated by subtotal thyroidectomy or radioactive iodine. J Clin Endocrinol Metab 50:1005. 1980.

7. Bech K, Madsen SN. Influence of treatment with radioiodine and propylthiouracil on thyroid stimulating immunoglobulins in Graves’ disease. Clin Endocrinol 13:417. 1980.

8. Atkinson S, McGregor AM, Kendall-Taylor P, Petersen MM, Rees Smith B. Effect of radioiodine on stimulatory activity of Graves’ immunoglobulins. Clin Endocrinol 16:537. 1982.

9. Hardisty CA, Fowles A, Munro DS. The effect of radioiodine and antithyroid drugs on serum long-acting thyroid stimulator protector (LATSP) A three-year prospective study. Clin Endocrinol 20:547. 1984.

10. Kasagi K, Iida Y, Konishi J, Misaki T, Arai K, Endo K, Torizuka K, Kuma K. Paired determination of thyroid-stimulating and TSH-binding inhibitory activities in patients with Graves’ disease during antithyroid drug treatment. Acta Endocrinol 111:474. 1986.

11. Bech K, Bliddal H, Siersbaek-Nielsen K, Friis T. Production of non-stimulatory immunoglobulins that inhibit TSH binding in Graves’ disease after radioiodine administration. Clin Endocrinol 17:395. 1982.

12. Hashim FA, Creagh FM, E1 Hawrani A, Parkes AB, Bukland PR, Rees Smith B. Characterization of TSH antagonist activity in the sera of patients with thyroid disease. Clin Endocrinol 25:275. 1986.

13. Southgate K, Creagh FM, Teece M, Kingwood C, Rees Smith B. A receptor assay for the measurement of TSH-receptor antibodies in unextracted serum. Clin Endocrinol 20:539. 1984.

14. Ambesi-Impiombato FS, Parkes LAM, Coon HG. Culture of hormone-dependent functional epithelial cells from rat thyroids. Proc Natl Acad Sci USA 77:3455. 1980.

15. Furmaniak J, Nakajima Y, Hashim FA, Creagh FM, Davies Jones E, Howells RD, McLachlan SM, Rees Smith B. The TSH receptor: Structure and interation with autoantibodies in thyroid disease. Acta Endocrinol Suppl 281:159. 1987.

16. Cho BY, Shong YK, Lee HK, Koh C-S, Min HK. Graves’ hyperthyroidism following primary hypothyroidism: sequential changes in various activities of thyrotropin receptor antibodies. Acta Endocrinol 120:447. 1989.